Introducing the “Hope in Action” Fireside Chat Series News Update May 28, 2026 Watch Episode 1 On Demand Here Progress in lupus research is accelerating, bringing new momentum, new possibilities, and new hope...
LRA Progress & Purpose Update | Albert T. Roy – May 2026 News Update May 26, 2026 Hear from President and CEO Albert T. Roy as he recaps the organization’s activations from Lupus Awareness, shining a...
Tell Congress Why Lupus Research Funding Must be a Priority News Update May 7, 2026 With your help, the Lupus Research Alliance has become the world’s largest funder of lupus research. The Lupus Research...
House Appropriations Committee Supports Lupus ABC News Update May 5, 2026 Great news! With a unanimous, bipartisan vote, the House Appropriations Committee adopted a provision supporting the Lupus Accelerating Breakthroughs...
Letter from LRA President & CEO Albert T. Roy News Update May 1, 2026 Dear Friends, Lupus Awareness Month begins today, and with it comes a renewed sense of purpose, momentum, and possibility. Thanks...
Saphnelo™ Approved as Self-Administered Autoinjector News Update April 27, 2026 The U.S. Food and Drug Administration just granted approval for a self-administered, once-weekly autoinjector of Saphenlo (anifrolumab), for the treatment of adult patients...
New Findings from Lupus Research Alliance-Funded Researcher Links Common Gut Bacteria to Lupus Flares News Update April 23, 2026 LRA-funded researcher Gregg Silverman, MD, NYU Grossman School of Medicine, is the lead author on a new study published...
FDA Accepts Application for Gazyva® (obinutuzumab) to Treat SLE News Update April 21, 2026 The U.S. Food and Drug Administration has accepted the supplemental Biologics License Application from Genentech for Gazyva® (obinutuzumab) to treat systemic lupus erythematosus (SLE), the most common form of...
New Phase 2 Data Showed that Litifilimab Significantly Reduced Disease Activity in Cutaneous Lupus Erythematosus News Update March 30, 2026 The Lupus Research Alliance welcomes new results from the Phase 2 part of the AMETHYST Phase 2/3 study, showing that the...
Submit a Lupus Awareness Month Proclamation in Your Community Story March 30, 2026 May is recognized worldwide as Lupus Awareness Month, a time when attention is focused on lupus, a serious, often overlooked, and frequently misdiagnosed autoimmune disease with...
LRA Progress & Purpose Update | Albert T. Roy – March 2026 News Update March 27, 2026 Hear from President and CEO Albert T. Roy as he recaps the organization’s exciting achievements from the first months...
New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE News Update March 6, 2026 A new Phase 3 study published in the New England Journal of Medicine found that Gazyva® (obinutuzumab) significantly reduced disease...